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The ﬁrst two steps in the mammalian lysine-degradation pathway are catalyzed by lysine-ketoglutarate reductase
and saccharopine dehydrogenase, respectively, resulting in the conversion of lysine to a-aminoadipic semialdehyde.
Defects in one or both of these activities result in familial hyperlysinemia, an autosomal recessive condition char-
acterized by hyperlysinemia, lysinuria, and variable saccharopinuria. In yeast, lysine-ketoglutarate reductase and
saccharopine dehydrogenase are encoded by the LYS1 and LYS9 genes, respectively, and we searched the available
sequence databases for their human homologues. We identiﬁed a single cDNA that encoded an apparently bifunc-
tional protein, with the N-terminal half similar to that of yeast LYS1 and with the C-terminal half similar to that
of yeast LYS9. This bifunctional protein has previously been referred to as “a-aminoadipic semialdehyde synthase,”
and we have tentatively designated this gene “AASS.” The AASS cDNA contains an open reading frame of 2,781
bp predicted to encode a 927-amino-acid-long protein. The gene has been sequenced and contains 24 exons scattered
over 68 kb and maps to chromosome 7q31.3. Northern blot analysis revealed the presence of several transcripts
in all tissues examined, with the highest expression occurring in the liver. We sequenced the genomic DNA from
a single patient with hyperlysinemia (JJa). The patient is the product of a consanguineous mating and is homozygous
for an out-of-frame 9-bp deletion in exon 15, which results in a premature stop codon at position 534 of the
protein. On the basis of these and other results, we propose that AASS catalyzes the ﬁrst two steps of the major
lysine-degradation pathway in human cells and that inactivating mutations in the AASS gene are a cause of
hyperlysinemia.
Introduction
In humans, lysine is an essential amino acid, and there
is no lysine biosynthetic machinery. However, humans
do degrade lysine and saccharopine, and this catabolic
pathway mirrors the terminal steps of lysine synthesis
in lower eukaryotes. Lysine is ﬁrst converted to sac-
charopine by the action of lysine-ketoglutarate reduc-
tase (LKR [E.C.1.5.1.7]). Saccharopine dehydrogenase
(SDH [E.C.1.5.1.9]) then converts saccharopine to a-
aminoadipate semialdehyde (ﬁg. 1). In the lysine bio-
synthetic pathway of Saccharomyces cerevisiae, these
two activities are encoded by two separate genes—LYS1
and LYS9, respectively (Bhattacharjee 1985). However,
in mammals, biochemical and genetic studies suggest the
existence of a bifunctional protein that possesses both
activities. Much of the data supporting the existence of
Received January 31, 2000; accepted for publication March 27,
2000; electronically published April 20, 2000.
Address for correspondence and reprints: Dr. Michael T. Geraghty,
The McKusick-Nathans Institute of Genetic Medicine, Blalock 1008,
The Johns Hopkins University School of Medicine, 600 North Wolfe
Street, Baltimore, MD 21287-4922. E-mail: geraghty@jhmi.edu
 2000 by The American Society of Human Genetics. All rights reserved.
0002-9297/2000/6606-0003$02.00
a bifunctional enzyme come from studies of familial hy-
perlysinemia (MIM 238700), a disorder that was ﬁrst
reported in individuals with physical and mental retar-
dation (Woody 1964). However, subsequent studies
identiﬁed pronounced hyperlysinemia in otherwise nor-
mal individuals, suggesting that hyperlysinemia alone
may not be associated with a clinical phenotype (Ozalp
et al. 1981). A biochemical analysis of these patients
indicated that defects in LKR were the cause of the hy-
perlysinemia (Dancis et al. 1969). It was later noted that
patients with these disorders often possessed a defect not
only in LKR activity but also in SDH activity, suggesting
the existence of a single locus encoding for both of these
activities (Dancis et al. 1976). The related disorder sac-
charopinuria is also thought to be caused by defects in
AASS (Cox and Dancis 1995). Additionally, biochemical
studies of bovine liver revealed that LKR activity and
SDH activity could not be puriﬁed away from each other,
and that the protein migrated as a single band of 116
kD on SDS-PAGE analysis (Markovitz et al. 1984; Mar-
kovitz and Chuang 1987). We report here the identiﬁ-
cation and characterization of the human gene encoding
a-aminoadipate semialdehyde synthase (AASS), the bi-
functional protein that contains both LKR activity and
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Figure 1 Human AASS, which catalyzes conversion of lysine to a-aminoadipic semialdehyde in the major lysine-degradation pathway
SDH activity. We demonstrate that mutations in AASS
are responsible for the autosomal recessive disorder fa-
milial hyperlysinemia.
Material and Methods
Cloning of Human AASS
To identify the gene defective in hyperlysinemia, we
used the BLAST algorithm to scan the human expressed-
sequence-tag database (dbEST) for any sequences with
the potential to encode proteins similar to either the
LYS1 protein or the LYS9 protein. Three overlapping
ESTs were identiﬁed as having similarity to LYS9, and
the longest was obtained and sequenced. This partial
cDNA clone contained, at its 5′ end, a short open reading
frame (ORF) that was homologous to a portion of LYS9.
However, this ORF was too short to encode an enzyme
with all the characteristics of LYS9, and we therefore
concluded that this cDNA was lacking sequences at its
5′ end.
Because there were no other clones for this cDNA in
dbEST, we also scanned the nonredundant database in
GenBank, for LYS1 and LYS9 homologues in other or-
ganisms. We identiﬁed in Caenorhabditis elegans a pre-
dicted bifunctional protein with an N-terminal domain
similar to that of LYS1 and a C-terminal domain similar
to that of LYS9. In addition, fragments of a Mus mus-
culus homologue of LYS1 and LYS9 were also identiﬁed
in this search. These protein sequences allowed us to
identify conserved peptides between C. elegans and M.
musculus, near the N-terminus of the LYS1 domain from
these species. Degenerate oligonucleotides (5′-GA(A/
G)GA(C/T)GT(A/C/G/T)AA(A/C/G)GC(A/C/T/G)TGG-
GA-3′ and 5′-AA(C/T)GC(A/C/T/G)TGGGA(A/G)(A/
C)G(A/C/T/G)CC(A/C/T/G)(C/T)T(A/C/T/G)GC(A/
C/T/G)CC-3′) encoding these peptides were then used in
conjunction with a gene-speciﬁc oligonucleotide (5′-CC-
AGTCGACGTTGGTCATGAAGCTTTCCTATGG-3′)
from the 3′ UTR of the human cDNA, to amplify a
fragment of the human LYS1/LYS9 cDNA, in a pair of
nested PCR reactions. The resulting PCR product was
sequenced in its entirety. Further sequences at the N-
terminus of LYS1 enzymes from other species led us to
conclude that this fragment was likely to lack ∼60 bp
of coding region, plus whatever 5′ UTR was present on
the corresponding transcript(s).
We employed a 5′ RACE (rapid ampliﬁcation of cDNA
ends) procedure to identify additional sequences at the
5′ end of this human cDNA. Marathon RACE human
liver cDNA (Clontech) was used as template with the
gene-speciﬁc antisense primer (5′-CAGGTAATGTAC-
CGTTGGATG-3′) and the adapter primer AP-1, in a
PCR reaction. The longest PCR product was sequenced,
and a full-length cDNA was assembled.
Genomic Structure and Chromosomal Localization
The genomic structure was obtained by use of the full-
length AASS cDNA to search the nonredundant nucle-
otide database, by means of the BLAST algorithm. A
single human genomic DNA PAC clone, DJ1049N15,
was identiﬁed (accession number AC006020). This
152,812-bp sequence contained segments that matched
all parts of the AASS cDNA sequence and previously
had been localized to chromosome 7q31.2-7q32. To
conﬁrm the chromosomal localization of AASS, we per-
formed FISH, as described elsewhere (Sigurðardo´ttir et
al. 1999). For this experiment, we used a mixture of
ampliﬁed genomic DNA covering exons 7–11 (∼3.2 kb)
and exons 21–24 (∼3 kb) as probes.
Transcript Analysis and Mutation Analysis
Tissue-expression analysis was performed by standard
protocols using multitissue northern blots from Clon-
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Figure 2 Alignment of S. cerevisiae LYS1 and LYS9 proteins with the bifunctional human protein AASS. Yeast LYS1 protein is aligned
with the N terminus of AASS, whereas yeast LYS9 protein is aligned with the C terminus of AASS. The junction between the yeast LYS1 and
LYS9 proteins is indicated the asterisk (*). Amino acid identities are shaded, and the amino acid positions are listed on the left. The N-terminus
of AASS is 20% identical to that of S. cerevisiae LYS1, whereas the C-terminus of AASS is 38% identical to that of S. cerevisiae LYS9.
tech, with the entire AASS cDNA being used as a probe.
For mutation analysis, genomic DNA was extracted
from the ﬁbroblasts of the patient, JJa (Dancis et al.
1976), and from wild-type ﬁbroblasts (Coriell Cell Re-
positories, GM05756). We then ampliﬁed each exon of
AASS from the two genomic DNA samples, using prim-
ers from the ﬂanking intronic regions. Each PCRproduct
was then gel-isolated and directly sequenced. For anal-
ysis of the patient’s mRNA levels, we extracted total
RNA from JJa and wild-type ﬁbroblasts (Coriell Cell
Repositories, GM05756 and GM08333). Northern blot
analysis was then performed by standard protocols,
again with the full-length AASS cDNA being used as a
probe. The same blots were probed with actin cDNA as
a control.
Results
Identiﬁcation of AASS
LKR and SDH are the ﬁrst two steps in the lysine-
degradation pathway in humans. Previous studies have
suggested that hyperlysinemia and saccharopinuria are
caused by a defect in a bifunctional protein with both
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Figure 3 Genomic structure of human AASS. At the top is a schematic representation of the genomic structure, showing the 24 exons
of AASS, which span ∼68 kb. Below this representation are the splice site junctions. All splice sites in AASS conform to the 5′)ag3′ rule.
LKR activity and SDH activity (Dancis et al. 1976). In
the present study, this bifunctional enzyme is referred to
as “AASS.” In the organism S. cerevisiae, which can
synthesize as well as degrade lysine, the ﬁnal two steps
in the biosynthetic pathway are the reverse reactions of
these two activities. Therefore, we used the two S. cer-
evisiae proteins, LYS1 and LYS9, to search the databases
for similar human sequences. Using a variety of com-
puter-based homology-probing approaches combined
with molecular-biology techniques (reverse-transcription
PCR, 5′-RACE, and DNA sequencing), we were able to
derive an apparently full-length human AASS cDNA se-
quence. The cDNA sequence can be found in GenBank
(accession number AF229180). This 2,987-bp cDNA
contains a 2,781-bp ORF and is predicted to encode a
926-amino-acid-long protein with a molecular mass of
102 kD and an isoelectric point (pI) of 6.2. The N-
terminal 374 amino acids display 20% amino acid iden-
tity to S. cerevisiae LYS1, whereas the C-terminal 552
amino acids display 38% sequence identity to S. cer-
evisiae LYS9 (ﬁg. 2).
Genomic Structure and Chromosomal Localization of
AASS
We used the BLAST algorithm to search the nonre-
dundant database for any genomic sequence correspond-
ing to that of the human AASS. The genomic clone
DJ1049N15 contained the entire AASS gene, and, using
the BLAST two-sequences algorithm, we were able to
deduce from this sequence the genomic structure of
AASS. The AASS gene covers a region of ∼68 kb and
contains 24 exons (ﬁg. 3). Exon 2 contains the ﬁrst ATG
of the ORF. All intron junctions conform to the
5′gt)ag3′ consensus. The sizes of the exons range from
60 bp (exon 14) to 225 bp (exon 4). Introns varied in
size from 96 bp to 11,400 bp, with an average length
of 2,860 bp. Several sequence-tagged sites within the
PAC containing the AASS gene had been mapped to the
long arm of chromosome 7, between the markers
D7S655 and D7S686, by radiation-hybrid mapping. To
conﬁrm this chromosomal localization by a different
technique, we performed FISH. Humanmetaphase chro-
mosomes were probed with the ampliﬁed genomicDNA,
and a speciﬁc signal for the gene was observed at 7q31.3,
a locus that corresponds well with the position deter-
mined by radiation-hybrid mapping (ﬁg. 4).
Tissue-Speciﬁc Expression of AASS
The expression of the AASS mRNA in various tissues
was analyzed by RNA hybridization. Northern blots
containing poly(A) RNA from 16 different tissue types
were hybridized with a radiolabeledAASS-speciﬁc probe
(ﬁg. 5). Three transcripts were identiﬁed in all tissues
examined. The major transcript was ∼7 kb, with lesser
bands at 9 kb and 3.4 kb. The 3.4-kb transcript is ap-
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Figure 4 Chromosomal localization of human AASS, by FISH. The arrow indicates the location of AASS on chromosome 7q31.3.
proximately the length predicted from our cDNA se-
quence after polyadenylation is taken into account. We
currently do not know the molecular structure of the
larger RNAs. However, the lack of any AASS homo-
logues in the sequence databases suggests that they may
be generated from the AASS gene reported here. In ad-
dition, we probed these same blots with the individual
halves of the gene that correspond to the two activi-
ties. We found no change in the banding pattern, sug-
gesting that these RNAs are all derived from the AASS
gene. One possibility is that these transcripts correspond
to incompletely spliced AASS heterogeneous nuclear
RNAs. In support of this hypothesis, we did identify
AASS ESTs that contained unspliced introns (GenBank
accession numbers AA928584 and AA721427). The
abundance of the AASS mRNA transcripts was varied,
with the highest expression in the liver and with high
expression in the heart and the kidney. The mRNA was
at low but detectable levels in all other tissues.
AASS Mutation in Hyperlysinemia
A number of clinical studies have demonstrated that
patients with hyperlysinemia are lacking in one or both
of the enzymatic activities LKR and SDH. These patients
have high levels of lysine in their plasma and urine, often
in conjunction with high levels of saccharopine. One
such patient, JJa, has been described (Dancis et al. 1976).
The product of a consanguineous marriage, JJa had se-
verely reduced activities of both LKR and SDH, ∼10%
and ∼3.5% of normal, respectively. We obtained a ﬁ-
broblast cell line from JJa, prepared genomic DNA, and
sequenced the exons of AASS. We identiﬁed a homo-
zygous 9- bp deletion in exon 15 from this patient, but
not from the control (ﬁg. 6A), and we conﬁrmed, by
PCR analysis, that this deletion was not present in 100
control alleles (data not shown). This deletion is out of
frame and results in a premature stop codon at the de-
letion junction at codon 534. This is predicted to reduce
mRNA levels, resulting in reduced levels of both activ-
ities, a possibility that is supported by the ﬁnding of low
activities of both LKR and SDH in this patient. To test
this hypothesis, we isolated total RNA from the ﬁbro-
blasts of JJa and from two unaffected ﬁbroblast cell lines
and performed a northern blot analysis, using the full-
length AASS cDNA as a probe. We found that, although
strong signals were detected for the AASS RNA from
the unaffected cell lines, there was no detectable signal
for the major 7-kb band in the RNA of JJa, and we
found that the other signals were also severely reduced
(ﬁg. 6B).
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Figure 5 Tissue-speciﬁc expression of human AASS. A multitissue Northern blot (Clontech) was probed with the full-length humanAASS.
Discussion
We report here the identiﬁcation and characterization of
a gene that encodes the human AASS protein. The N
terminus of the predicted protein is 20% identical to
that of the yeast LYS1, whereas the C terminus of the
predicted protein is 38% identical to the yeast LYS9. In
yeast, at least part of the lysine biosynthetic pathway is
known to be peroxisomal, since two of the lysine bio-
synthetic enzymes, LYS1 and LYS4, terminate in per-
oxisomal targeting signals and have been demonstrated
to be peroxisomal (Geraghty et al. 1999). The peroxi-
some also plays a known role in mammalian lysine
metabolism. In addition to the major route of lysine
metabolism, which degrades lysine via saccharopine, a
minor route exists, which degrades lysine via pipecolate.
This minor pathway is peroxisomal, and, although it is
primarily used for D-lysine degradation, it is also the
major pathway for L-lysine degradation in the brain
(Chang 1978; Giacobini et al. 1980). These two path-
ways converge at aminoadipic semialdehyde. The per-
oxisomal localization of both the yeast lysine biosyn-
thetic pathway and the minor catabolic pathway in
humans suggests the possibility that the major catabolic
pathway in humans may also be peroxisomal. The per-
oxisomal signal type 1 (PTS1) is an obligately C-terminal
tripeptide of sequence Ser-Lys-Leu (SKL*) and variants
(Gould et al. 1988). Both the mouse and human AASS
enzymes terminate in sequences that may represent yet
another set of PTS1 variants, with the mouse AASS ter-
minating in Ile-Lys-Leu (IKL*) and with the human
AASS terminating in the sequence Ile-Lys-Pro (IKP*).
We found that the AASS gene includes 24 exons that
span ∼68 kb and is localized to chromosome 7q31.3.
Analysis of the AASS transcripts revealed expression in
all tissues examined, with highest expression in the liver.
The liver is the site of the majority of amino acid me-
tabolism, and, therefore, this ﬁnding is in agreement
with the expected pattern for this enzyme.
In addition, we have identiﬁed a homozygous deletion
in this gene in a patient with hyperlysinemia, a disorder
that results from reduced activity of LKR and/or of
SDH. The 9-bp deletion is out of frame and results in
the formation of a stop codon across the deletion,
resulting in a predicted protein that lacks the 393 C-
terminal amino acids and most of the putative SDH
domain. Previous studies had demonstrated that this
patient had only 3.5% of wild-type SDH activity. In
addition, the LKR activity in this patient also was se-
verely reduced, to only 10% of normal (Dancis et al.
1976). The reduction in the activities of both LKR and
SDH in this patient suggests that this premature stop
codon also affects AASS mRNA processing or stability.
This theory is supported by our ﬁnding that ﬁbroblasts
from JJa had undetectable levels of the major AASS
mRNA band and had lowered levels of the other bands.
The related disorder saccharopinuria also has been sug-
gested to result from mutations in the AASS gene. Pa-
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Figure 6 Mutation and expression analysis of AASS in hyper-
lysinemia. (A) Direct sequence analysis of an unaffected individual and
JJa, a hyperlysinemic individual, demonstrating the 9-bp deletion in
the AASS gene of JJa. The stop codon created by the out-of-frame
deletion is underlined. The homozygous nature of the JJa sequence as
well as the consanguineous nature of the parents suggests that the
mutation is homozygous. (B) Northern blot of patient RNA and nor-
mal RNA. The top panel shows the blot probed with the AASS cDNA,
while the lower panel shows the same blot probed with actin cDNA
as a control.
tients with this disorder have both hyperlysinemia and
saccharopinuria, although the saccharopinuria is much
more severe. The few patients with saccharopinuriawho
have been studied suffer from neurological deﬁcits, al-
though the relation of the saccharopinuria to these
symptoms is unclear (Cox and Dancis 1995). Although
we were unable to obtain cell lines from patients with
saccharopinuria, it seems likely that this less common
disorder results from speciﬁc mutations in the portion
of AASS encoding SDH, which could explain the high
levels of saccharopine, compared with that in patients
with hyperlysinemia.
One of the interesting aspects of this metabolic path-
way is the union of two single-function enzymes into
one multifunctional enzyme. Lower eukaryotes such as
S. cerevisiae have two distinct genes, one encoding for
LKR activity and another encoding for SDH activity.
Biochemical evidence previously presented had sug-
gested the existence of a single gene encoding for the
activities of both LKR and SDH in humans. We have
conﬁrmed this hypothesis, by the cloning of human
AASS. Other higher eukaryotes, including C. elegans
and plants (Epelbaum et al. 1997), also seem to have
evolved a single-gene locus for these two activities.
There could be a number of advantages to the joining
of these two enzymatic activities into a single-gene lo-
cus. One possibility is the kinetic advantage of substrate
channeling. By fusing the two activities together, the
apparent KM (Michaelis constant) for the substrates
could decrease because the obstacle to diffusion has
been overcome. A good example of this phenomenon
is the bifunctional enzyme UMP synthase. This protein
contains both orotate phosphoribosyltransferase activ-
ity and orotidine-5′-phosphate decarboxylase activity,
and the substrate channeling of this enzyme is much
higher than when the enzyme activities are in individual
proteins (Pragobpol et al. 1984). Another possibility is
that the fusion of the two activities into a single protein
causes the protein to favor the degradation of lysine.
This could explain the ability of S. cerevisiae to syn-
thesize lysine with its two separate proteins, LYS1 and
LYS9, whereas the bifunctional AASS serves to catalyze
lysine degradation only. Future studies will allow us to
elucidate the localization of lysine metabolism within
the cell, as well as to assess the effects of bifunctionality
versus monofunctionality for these two enzyme activi-
ties, which might suggest an evolutionary reason for
this change.
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